Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PERIMAX
2010-023575-25Phase 2Terminated
- Sponsor
- University of Regensburg
- Start
- Dec 2011
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of fluorouracil, oxaliplatin, irinotecan, bevacizumab and folinic acid in colorectal cancer (CRC) (2 arms), sponsored by University of Regensburg. Primary endpoint: Failure-free survival rate at 18 months. Started Dec 2011; status: terminated.
02
Drugs
fluorouraciloxaliplatinirinotecanbevacizumabfolinic acid
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2010-023575-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-023575-25.